首页> 外文OA文献 >Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

【2h】

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

机译：AZD8835的间歇高剂量调度，PI3Kα和PI3Kδ的新选择性抑制剂，证明了PIK3CA依赖性乳腺癌的治疗策略

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Kevin Hudson; Urs J. Hancox; Cath Trigwell; Robert McEwen; Urszula M. Polanska; Myria Nikolaou; Pablo Morentin Gutierrez; Alvaro Avivar-Valderas; Oona Delpuech; Phillippa Dudley; Lyndsey Hanson; Rebecca Ellston; Alys Jones; Marie Cumberbatch; Sabina C. Cosulich; Lara Ward; Francisco Cruzalegui; Stephen Green;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K alpha and PI3K delta, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers [J] . Hudson Kevin, Hancox Urs J., Trigwell Cath, Molecular cancer therapeutics . 2016 ,第5期

机译：新型PI3K alpha和PI3Kδ选择性抑制剂AZD8835的间歇高剂量计划展示了PIK3CA依赖性乳腺癌的治疗策略
2. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl) pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl) piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3K alpha and PI3K delta for the treatment of cancers [J] . Barlaam Bernard, Cosulich Sabina, Delouvrie Bebedicte, Bioorganic and Medicinal Chemistry Letters . 2015 ,第22期

机译：1-（4-（5-（5-氨基-6-（5-叔丁基-1,3,4-恶二唑-2-基）吡嗪-2-基）-1-乙基-1,2的发现，4-triazol-3-yl）piperidin-1-yl）-3-hydroxypropan-1-one（AZD8835）：一种有效且选择性的PI3Kα和PI3Kδ抑制剂，用于治疗癌症
3. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER plus breast cancer [J] . Bean Jennifer R., Hosford Sarah R., Symonds Lynn K., Breast cancer research and treatment. . 2015 ,第1期

机译：PI3K / mTOR双重抑制剂P7170表现出对内分泌敏感和内分泌抵抗性ER加乳腺癌的有效活性
4. QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents [C] . Jelena Oluic, Katarina Nikolic, Mica Vucicevic International Conference on Medical and Biological Engineering . 2017

机译：基于QSAR建模和基于结构的新PI3K / MTOR抑制剂的虚拟筛选潜在抗癌剂
5. Synthesis and screening of PI3K inhibitor prodrugs for treatment of prostate cancer [D] . Pinder, Tanya 2012

机译：PI3K抑制剂治疗前列腺癌的前药的合成与筛选
6. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835 a novel PI3Kα inhibitor [O] . Juliana Maynard, Sally-Ann Emmas, Francois-Xavier Ble, -1

机译：使用18F-氟-脱氧-葡萄糖正电子发射断层显像（18F-FDG PET）作为非侵入性药效生物标记物来确定新型PI3Kα抑制剂AZD8835的最低药理活性剂量
7. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors [O] . M. Brandão, R. Caparica, D. Eiger, 2019

机译：雌激素受体阳性乳腺癌患者的响应和抗PI3K抑制剂的生物标志物及涉及PI3K抑制剂的组合疗法

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

著录项

相似文献

相关主题

期刊订阅